相似文献
1
[Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
Dtsch Med Wochenschr. 2008 Sep;133(38):1917-21. doi: 10.1055/s-0028-1085577. Epub 2008 Sep 10.
2
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
Am J Gastroenterol. 1996 Mar;91(3):423-33.
3
Position statement: immunomodulator therapy for inflammatory Bowel disease.
Isr Med Assoc J. 2003 Mar;5(3):164-9.
4
General principles of medical therapy of inflammatory bowel disease.
Gastroenterol Clin North Am. 2004 Jun;33(2):191-208, viii. doi: 10.1016/j.gtc.2004.02.003.
5
Azathioprine and mercaptopurine: lymphoma.
Prescrire Int. 2011 May;20(116):126.
6
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
Gastroenterol Clin North Am. 2004 Jun;33(2):209-34, viii. doi: 10.1016/j.gtc.2004.02.004.
7
[Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Dtsch Med Wochenschr. 2003 Feb 21;128(8):378-85. doi: 10.1055/s-2003-37378.
8
[Use of immunosuppressors in chronic inflammatory intestinal diseases].
Gastroenterol Clin Biol. 1999 Jun;23(5 Pt 2):B178-88.
9
Inflammatory bowel disease: management issues during pregnancy.
Arch Gynecol Obstet. 2004 Sep;270(2):79-85. doi: 10.1007/s00404-003-0489-6. Epub 2003 Apr 30.
10
Review article: monitoring of immunomodulators in inflammatory bowel disease.
Aliment Pharmacol Ther. 2005 Feb 15;21(4):307-19. doi: 10.1111/j.1365-2036.2005.02343.x.
Zotero 插件